Related Experiment Videos
Safety issues related to DMARD therapy.
1Department of Medicine, Stanford University School of Medicine, CA.
The Journal of Rheumatology. Supplement
|November 1, 1990
Summary
The traditional rheumatoid arthritis treatment pyramid is outdated. Newer data show disease modifying antirheumatic drugs are safer than previously thought, challenging old treatment strategies.
Area of Science:
- Rheumatology
- Pharmacology
- Clinical Medicine
Background:
- The traditional pyramidal approach to rheumatoid arthritis (RA) treatment assumed most effective drugs were most toxic.
- This strategy prioritized less toxic, less effective drugs initially.
- It also assumed similar toxic-therapeutic ratios across drug classes.
Purpose of the Study:
- To re-evaluate the fundamental assumptions of the traditional pyramidal treatment strategy for RA.
- To analyze recent data on drug toxicity and safety profiles in RA management.
- To inform potential shifts in RA monitoring and treatment strategies.
Main Methods:
- Review of recent clinical data and safety records for RA medications.
- Analysis of toxic-therapeutic ratios for different classes of RA drugs.
- Comparative assessment of traditional versus modern treatment strategy assumptions.
Main Results:
- Recent data indicate severe toxicity associated with nonsteroidal anti-inflammatory drugs (NSAIDs).
- Certain disease modifying antirheumatic drugs (DMARDs) exhibit a favorable safety profile.
- These findings contradict the core tenets of the old pyramidal approach.
Conclusions:
- The fundamental assumptions underpinning the traditional pyramidal strategy for RA treatment are inaccurate.
- Newer analyses suggest less aggressive monitoring strategies may be appropriate.
- Evidence supports a re-evaluation of RA treatment paradigms based on current drug safety data.